A better treatment for river blindness is available, but companies didn't pursue it because it's not profitable. Now, a non-profit pharma company has brought that new treatment all the way through regulatory approval without a commercial partner - a notable first. www.nature.com/articles/d44...
A novel financing model rescued moxidectin from abandonment. The path to getting the drug manufactured and distributed exposes deeper faultlines in global health systems
